Tag: Pfizer

Pfizer-BioNTech potential COVID-19 vaccine shows promise in additional data

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

German biotech firm BioNTech and US drugmaker Pfizer on Monday reported additional data from their experimental COVID-19 vaccine that showed it was safe and induced an immune response in patients.

The companies said the data also demonstrated an induction of high level of T-cell responses against the novel coronavirus.

More than 150 possible vaccines are being developed and tested around the world to try to stop the pandemic. There are 23 candidates in human clinical trials, including from Moderna and AstraZeneca Plc.

Experts have cautioned a safe and effective vaccine will take 12-18 months to develop.

The results were disclosed from a trial in Germany testing 60 healthy volunteers, and come after the companies earlier this month reported data from a corresponding early-stage trial in the United States.

Also Read: Oxford COVID-19 vaccine human trial: Early data shows it is safe, well-tolerated and immunogenic

The trial showed that volunteers given two doses of the vaccine produced virus-neutralizing antibodies, similar to the US trial. The data is available on an online preprint server at medrxiv and is undergoing scientific peer-review for potential publication, the companies said.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Closing Bell: Market ends over 1% higher led by auto, IT stocks; M&M, Hero MotoCorp top gainers, surge upto 6%

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Indian equity benchmark indices extended gains to close higher on Thursday for the second consecutive day supported by auto and IT stocks. Broad based buying was witnessed across sectors that led to the rally.

At close, the Sensex ended 429 points or 1.21 percent higher to 35,843.70 while the Nifty index ended at 10,552, 122 points or 1.17 percent higher.

Broader markets traded in-line with the benchmarks, with Nifty Midcap100 and Nifty Smallcap 100 ending 1.13 percent and 0.89 percent higher.

Nifty Auto was the best-performing sector of the day, closing nearly 3 percent higher followed by Nifty IT (+2.65 percent) and Nifty Metal (0.98 percent). Meanwhile, Nifty Bank traded in the red at closing, down 0.11 percent.

M&M, Hero MotoCorp, Cipla, Titan and HCL Technologies were the Nifty50 index gainers of the day while Axis Bank, UPL, Vedanta, Hindustan Unilever and Eicher Motors remained the top losers of the day.

The Indian currency appreciated 56 paise to settle at 75.04 (provisional) against the US dollar tracking weakness in the greenback and gains in the domestic equity market. It had settled at 75.60 against the greenback on Wednesday.

Pfizer’s shares surged over 8 percent on Thursday after the firm’s US arm said that the COVID-19 vaccine developed by it with Germany-based BioNTech has shown potential. The vaccine was found to be safe and well-tolerated in the early-stage human trials, the companies said.

Market breadth remained in favour of the advances today. 1,090 stocks in the NSE ended with gains while 720 ended with losses.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer surges over 8% after parent firm’s COVID-19 vaccine shows potential

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The share price of pharma company Pfizer India surged over 8 percent on Thursday after the firm’s US arm said that the COVID-19 vaccine developed by it with Germany-based BioNTech has shown potential. The vaccine was found to be safe and well-tolerated in the early-stage human trials, the companies said.

The stock rose as much as 8.5 percent to Rs 4,313.4 per share on the BSE. At 12:58 pm, the stock was trading at Rs 4,151 per share, up 4.44 percent.

The drug is one of the 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.

No COVID-19 vaccine has yet been approved for commercial use. A Massachusetts Institute of Technology analysis last year found that about one in three vaccines in the first stage of testing later gains approval.

“These first trial results show that the vaccine yields immune activity and causes a strong immune response,” said BioNTech’s co-founder and CEO Ugur Sahin.

The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.

Pfizer and Germany’s BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. and dozens of other biopharmaceutical outfits and academic groups to come up with a safe and effective vaccine against COVID-19. With almost 10.5 million confirmed cases around the globe and over half a million deaths, drugmakers are under increasing pressure to deliver.

Catch all live market action here

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

A COVID-19 vaccine developed by German biotech firm BioNTech and US pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.

The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.

BioNTech’s shares were up about 8 percent, after rising as much as 19 percent to reach their highest in more than three months.

Pfizer stock also gained, rising 4.4 percent to USD 34.13. In turn, shares in some rival vaccine developers, such as Moderna and Novavax Inc dropped.

BioNTech said testing of two dosages of its BNT162b1 drug on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.

It said the higher of the two doses – both administered via two injections within three weeks of one another – was followed by a short fever in three out of four participants after the second shot.

A third dosage, tested at a higher concentration in a separate group, was not repeated after the first shot because of injection pain.

“These first trial results show that the vaccine yields immune activity and causes a strong immune response,” said BioNTech’s co-founder and Chief Executive Officer Ugur Sahin.

He said larger trials were being prepared to show whether this translates into protection against a real infection.

“While more work needs to be done, we believe the benefits appear to outweigh the risks so far, especially when considering the disease the vaccine is trying to prevent,” Mizuho Securities analyst Divan Vamil said in a note.

Bernstein analysts said their initial impression was that the data was “solid”, but noted they don’t expect the initial generation of vaccines to be silver bullets in terms of conferring nearly complete protection.

PEER REVIEW

No COVID-19 vaccine has yet been approved for commercial use. A Massachusetts Institute of Technology analysis last year found that about one in three vaccines in the first stage of testing later gains approval.

BioNTech, which listed on the U.S. Nasdaq in October, said the data demonstrated that BNT162b1 could be administered in a dose that was well tolerated with only temporary side effects.

Early-stage human trials of vaccines are designed to measure certain antibodies and other immune markers in the blood as an indicator of the body’s readiness to fight an infection that then requires further validation.

The pharmaceutical industry is eager to launch larger follow-up trials to see how vaccinated participants react to real infections over longer periods.

Brokerage SVB Leerink said these larger studies are required for vaccine approval and adoption, and the timing for approval will be dependent on the trials and their results, and not more abbreviated smaller interim studies.

BioNTech and Pfizer will now pick the most promising of four experimental vaccines for a trial involving up to 30,000 healthy participants, which is likely to begin in the United States and Europe in late July, if it gets the regulatory green light.

If it eventually gets marketing approval, the companies are gearing up to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States.

Results from early-stage testing of BioNTech’s three other potential vaccines are yet to be published.

The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said.

The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. Translate Bio and its partner Sanofi are also working on a messenger RNA vaccine for COVID-19.

Biotech investors Thomas and Andreas Struengmann, who sold their generic drugs business Hexal to Novartis in 2005, are major shareholders of BioNTech.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Singapore scientists to start human trials of COVID-19 vaccine in August

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Singapore scientists testing a COVID-19 vaccine from US firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.

More than 100 vaccines are being developed globally, including several already in human trials from the likes of AstraZeneca and Pfizer, to try and control a disease that has infected more than 8 million people and killed over 430,000 worldwide.

The vaccine being evaluated by Singapore’s Duke-NUS Medical School works on the relatively-untested Messenger RNA (mRNA) technology, which instructs human cells to make specific coronavirus proteins that produce an immune response.

“The fact that it replicates and triggers a very balanced immune response, both in terms of the antibody and killer cells – those are welcome properties,” Ooi Eng Eong, deputy director of the school’s emerging infectious diseases programme, told Reuters on Tuesday.

Antibodies stick to the virus and prevent it from infecting cells, while killer cells, another arm of the immune system, recognise infected cells and destroy them, he said.

The mRNA approach has not yet been approved for any medicine so its backers, which also include US biotech firm Moderna, are treading uncharted territory.

Because of that, Ooi said longer studies were needed to ensure its safety.

“The most optimistic case is that it’s about this time next year, that we will have a vaccine,” Ooi said.

Ooi is also working on a monoclonal antibody treatment for COVID-19 and will begin safety trials on healthy people this week, before testing on COVID-19 patients in the coming months.

Ooi said potential deployment of the treatment could be faster than the vaccine, without giving an exact timeline.

Antibodies are generated in the body to fight off infection. Monoclonal antibodies mimic natural antibodies and can be isolated and manufactured in large quantities to treat diseases.

Tiny city-state Singapore has one of the highest infection tallies in Asia, with more than 40,000 cases, largely due to mass outbreaks in dormitories for its migrant workers.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer Ltd Q4 net profit declines 6% to Rs 103 crore

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Drug firm Pfizer Ltd on Monday reported a 5.90 per cent decline in net profit at Rs 103.01 crore for the quarter ended March 31, 2020.

The company had posted a net profit of Rs 109.47 crore in the corresponding period of the previous fiscal, Pfizer said in a filing to the BSE.

Revenue from operations stood at Rs 502.01 crore for the quarter under consideration. It was at Rs 535.66 crore in the same period a year ago, it added.

For 2019-20, the company’s net profit stood at Rs 509.13 crore as against Rs 429.05 crore in 2018-19, Pfizer said.

The company’s revenue from operations stood at Rs 2,151.65 crore for the fiscal year ended March 2020. It was at Rs 2,081.50 crore in 2018-19.

The company’s board of directors have recommended a final dividend of Rs 10 per equity share of Rs 10 each for the financial year ended March 31, 2020, Pfizer said.

Shares of Pfizer Ltd on Monday closed 0.41 per cent higher at Rs 4,078.15 per scrip on the BSE.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Trump administration selects five coronavirus vaccine candidates as finalists, says report

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.

The other companies are Johnson & Johnson and Merck & Co Inc, according to the paper.

The selected companies will get access to additional government funds, help in running clinical trials, and financial and logistical support, the paper reported.

There is no approved vaccine for COVID-19, the respiratory disease caused by the new coronavirus.

The report did not mention potential vaccines from French drugmaker Sanofi, Novavax Inc and Inovio Pharmaceuticals Inc – among the more than 100 vaccines in development globally.

The announcement of the decision will be made at the White House in the next few weeks, the report said.

The White House did not immediately respond to a request for comment.

“We cannot comment on information that is market-moving,” a US Department of Health and Human Services official said.

The companies on the list are the farthest along in developing a vaccine and have significant manufacturing capacity.

The United States is planning massive clinical trials involving 100,000 to 150,000 volunteers in total, with the goal of delivering an effective vaccine by the end of this year. To make that deadline, the government aims to start mid-stage testing in July.

The first two vaccines to start mid-stage trials would likely be from Moderna and the AstraZeneca/Oxford University combination, the director of the National Institutes of Health, Dr. Francis Collins, told Reuters in an interview last month. He said he expected vaccine candidates from J&J and Merck to eventually join the trial effort.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on Tuesday that he hoped to have “a couple hundred million doses” by the start of 2021, according to a CNN report.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer CEO claims COVID-19 vaccine could be ready by October end, says report

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

American pharmaceutical company Pfizer believes that a COVID-19 vaccine could be ready by the end of October 2020, reported The Times of Israel, citing Albert Bourla, the CEO of the firm.

“If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can… have a vaccine around the end of October,” Bourla was quoted as saying in the report.

Also read: COVID-19: Besides Moderna, these are the other leading efforts in finding a coronavirus vaccine

Pfizer is working with German firm Biontech for several possible vaccines in Europe and the United States, said the report.

Besides, the report also quoted AstraZeneca boss who said that one or more vaccines could begin rolling out by the end of the year. AstraZeneca, in partnership with the University of Oxford, is working to come up with a vaccine and expects at least one could be ready by the end of 2020.

“The hope of many people is that we will have a vaccine, hopefully several, by the end of this year,” Pascal Soriot, head of AstraZeneca, was quoted in the report as saying.

Also read: First COVID-19 vaccine human trial finds it is safe, induces immune response

He, however, said that “we are running against time”. The deadly virus has killed over 358,000 people and infected more than 5 million worldwide so far.

The report also highlighted the warnings from experts saying the challenges could be “daunting” as the estimates show that about 15 billion doses would be required to stop the pandemic.

Also read: How one Indian company could be world’s door to a COVID-19 vaccine

According to the report, Soriot said that one of the challenges in coming up with a vaccine was declining transmission rates as it will be difficult “to properly conduct clinical vaccine trials in a natural setting”.

More than 100 labs across the world are working to develop a vaccine against the deadly virus. Of these, ten have made to the clinical trial stage.

Also read: Italian scientists claim to have developed vaccine that neutralises coronavirus in human cells

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer, BioNTech begin coronavirus vaccine trial in the US

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Pfizer Inc and BioNTech on Tuesday announced that they have begun initial human trial of their coronavirus vaccine. If the vaccine proves to be safe and effective in trials, it could potentially be ready for US distribution by the end of the year.

In the first stage of study, the vaccine will be administered on healthy adults of 18-55 years of age. Older adults will only be immunised with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity, Pfizer said in a statement.

The first participants have been dosed in the US in a clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

“The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age).”

“With our unique and robust clinical study program underway, starting in Europe and now the US, we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” said Albert Bourla, chairman and CEO, Pfizer.

“ The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,”

Pfizer and BioNTech’s development program includes four vaccine candidates, each representing a different combination of mRNA format and target antigen.

The novel design of the trial allows for the evaluation of the various mRNA candidates simultaneously in order to identify the safest and potentially most efficacious candidate in a greater number of volunteers, in a manner that will facilitate the sharing of data with regulatory authorities in real time, it said.

“It is encouraging that we have been able to leverage more than a decade of experience in developing our mRNA platforms to initiate a global clinical trial in multiple regions for our vaccine program in such a short period. We are optimistic that advancing multiple vaccine candidates into human trials will allow us to identify the safest, most effective vaccination options against COVID-19,” said Ugur Sahin, CEO and co-founder of BioNTech.

During the clinical development stage, BioNTech will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.

In anticipation of a successful clinical development program, Pfizer and BioNTech are working to scale up production for global supply.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Kotak Bank, Pfizer among top 5 breakout buys that could give 10-18% return

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

On February 12, Nifty saw a gap-up opening and after early gains, the index continued to trade in a range for the rest of the session. The Nifty closed at 12,201 up by 0.77 percent.

Broader market indices underperformed the benchmark with the S&P BSE Midcap and BSE Smallcap down by 0.29 percent and 0.13 percent, respectively, for the day.

The market breadth on the NSE was negative with the advance-decline ratio of 2:3. The Nifty has seen a strong bounce back from the Budget 2020 low of 11,614.

The congestion zone is placed at 12,272, but a close above this level could take the index towards 12,500 levels. On the downside, the immediate support is seen at 12,100 and then towards 11,990 levels.

In Nifty February monthly expiry options, maximum open interest for Put is seen at strike price 12,000 and 11,800; while for Call, maximum open interest is seen at 12,500 followed by 12,400.

Put writing was seen in the immediate strike price indicating supports are shifting higher. The Nifty options distribution is suggesting a range of 12,500-12,000 for the market.

India VIX closed at 13.15 down by 1.86 percent on Wednesday. VIX has come off its highs post Budget. Sustaining below 14 levels expect a further decline in VIX.

Here is a list of top five stocks which could give 10-18% returns in the next 1-3 months:

Kotak Mahindra Bank: Buy| LTP: Rs 1714| Stop Loss: Rs 1,660| Target: Rs 1,880| Upside 10%

The stock is in an uptrend forming higher tops and high bottoms on the weekly chart. It touched a high of Rs 1,735 in December last year and then corrected down towards Rs 1,576 levels.

The stock took support around rising trend line connecting lows of Rs 1,002 and Rs 1,399 and then bounced back. On the daily chart, the stock has formed a bullish inverted head and shoulders pattern between 1729 and 1576 levels.

It is currently trading below the breakout level, but should eventually see a breakout on the upside after Wednesday’s rally.

The Relative Strength Index (RSI) and Stochastic have given a positive crossover with their respective averages on the daily as well as on the weekly chart.

MACD is turning up from the equilibrium level of zero on the daily chart. Thus, the stock can be bought at current levels and on dips towards Rs 1,690 with a stop loss below Rs 1,660, and a target of Rs 1,880 levels.

Pfizer: Buy| LTP: Rs 4,462| Stop Loss: Rs 4,250| Target: Rs 5,100| Upside 14%

The stock after consolidating between 3850-2650 odd levels witnessed a breakout to hit an all-time high of 4499 in December last year.

Since then, the stock has been consolidating between 4490-3950 levels above the breakout level. Price momentum and volume action this week suggests that the stock is likely to see a breakout on the upside.

Price has given a breakout on the upside from Bollinger Band. MACD has given a positive crossover with its average above equilibrium level of zero on the daily chart. Thus, the stock can be bought at current levels and on dips towards 4375 with a stop loss below 4250, and a target of 5100 levels.

Mahanagar Gas: Buy| LTP: Rs 1,224| Stop Loss: Rs 1,160| Target: Rs 1,400| Upside 14%

The stock witnessed consolidation at lower levels between 1065 and 755 odd levels for almost one year.  It has formed a bullish double-bottom reversal pattern on the weekly chart.

The stock has given a breakout from the pattern on strong momentum and high volumes indicating the start of a fresh uptrend.

For the last couple of weeks, the stock has been consolidating in the range of 1246-1143 post the breakout up move. After yesterday’s up move stock is suggesting a resumption of the uptrend.

Relative Strength Index has given a positive crossover with its average on the daily chart. Thus, the stock can be bought at current levels and on dips towards Rs 1,160 with a stop loss below Rs 1,160, and a target of Rs 1,400 levels.

Dabur India Ltd: Buy| LTP: Rs 519| Stop Loss: Rs 495| Target: Rs 600| Upside 15%

The stock has seen major consolidation between 490 and 360 odd levels over the 17-months period. It has formed a bullish W-shaped pattern on the weekly chart.

The stock has given a breakout from the pattern and hit an all-time high of 523 in Wednesday’s session. Price has given a breakout on the upside from Bollinger Band with the expansion of bands on the daily chart indicating a continuation of the trend in the direction of the breakout.

The relative strength index has given a positive crossover with its average on the daily chart. Thus, the stock can be bought at current levels and on dips towards 511 with a stop loss below 495, and a target of 600 levels.

Cholamandalam Investment and Finance: Buy| LTP: Rs 339| Stop Loss: Rs 320| Target: Rs 400| Upside 18%

For the last 21-months, the stock has been trading between 352 and 207 to form a base. The stock has been trending higher since its October’18 low of 207.

After the breakout above the congestion zone of Rs 335-310, the price has taken support at the neckline level. It has formed a bullish pole and pennant pattern on the daily chart which is a short term continuation pattern.

The Average Directional Index (ADX) line, an indicator of trend strength has moved above the equilibrium level of 20 with rising Plus Directional line on the daily chart.

Thus, the stock can be bought at current levels and on dips towards Rs 333 with a stop loss below Rs 320, and a target of Rs 400 levels.

-by Ashish Chaturmohta, Head of Technical and Derivatives, Sanctum Wealth Management

(Source: Moneycontrol.com)

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow